Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,019 matching trials from the live ClinicalTrials.gov search.
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Conditions
Esophagogastric Cancer, HER2-Negative
Interventions
regorafenib, nivolumab, FOLFOX chemotherapy with oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Head and Neck Neoplasms, Head and Neck Lymphedema, Head and Neck Cancer
Interventions
Head and neck garments for pneumatic compression device, NIRFLI with ICG
Device · Drug
Lead sponsor
Tactile Medical
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer
Interventions
Collection of biological specimens
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Oral Leukoplakia
Interventions
aminolevulinic acid hydrochloride, photodynamic therapy, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Conditions
Thyroid Neoplasms
Interventions
AG013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
Conditions
Papillary Thyroid Microcarcinoma
Interventions
Active Surveillance
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm, Malignant Head and Neck Neoplasm, Malignant Nervous System Neoplasm, Malignant Solid Neoplasm, Malignant Thoracic Neoplasm, Skin Neoplasm, Soft Tissue Neoplasm, Central Nervous System Neoplasm, Endocrine Gland Neoplasms
Interventions
Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
Interventions
INCA00186, Retifanlimab, INCB106385
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
Conditions
Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Interventions
M1231
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Avelumab, Palbociclib, Cetuximab
Drug
Lead sponsor
Kathryn Gold
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Terminated Phase 2 Interventional Results available

Ruxolitinib in Operable Head and Neck Cancer

NCT03153982
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ruxolitinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Tucson, Arizona • San Francisco, California
Conditions
Neoadjuvant Treatment, Thyroid Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, docetaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
160
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
Conditions
Head Neck, Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, Magrolimab, cetuximab, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Cancer Metastatic
Interventions
Nivolumab 480mg and surgical resection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Thyroid Cancer
Interventions
Temsirolimus and Sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Oropharyngeal Neoplasms, Head and Neck Cancer
Interventions
Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Thyroid Cancer
Interventions
KTN3379, vemurafenib
Biological · Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
Interventions
Combination of Varlilumab and Atezolizumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Head and Neck Cancer
Interventions
proteomic profiles
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee